Trial reportCritical care (London, England)2010
Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit.
Trial report in Critical care (London, England), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Japanese clinical practice guideline for acute kidney injury 2016.Clinical and experimental nephrology · 2018Guideline
- Accuracy of cystatin C for the detection of abnormal renal function in children undergoing chemotherapy for malignancy: a systematic review using individual patient data.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2018Pooled it
- Acute kidney injury biomarker responses in young and older female adults following mild hypohydration.American journal of physiology. Renal physiology · 2026Trial
- Urinary cystatin C and acute kidney injury after cardiac surgery.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2013Trial
- Diagnostic value of urine sCD163 levels for sepsis and relevant acute kidney injury: a prospective study.BMC nephrology · 2012Trial
- Multiplexed plasmon-enhanced lateral flow assay for early diagnosis of acute kidney injury.Biosensors & bioelectronics · 2026Article
- Combined Predictive Value of Serum NGAL, CysC, Urinary NAG, and eGFR for Sepsis-Associated Acute Kidney Injury in Patients in ICU.Saudi medical journal · 2026Article
- Biomarker-Based Diagnosis and Risk Stratification in Sepsis-Associated Acute Kidney Injury: From Molecular Mechanisms to Multimarker Panels.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Hydration Status and Acute Kidney Injury Biomarkers in NCAA Female Soccer Athletes During Preseason Conditioning.Nutrients · 2025Article
- Integration of FTIR Spectroscopy and Machine Learning for Kidney Allograft Rejection: A Complementary Diagnostic Tool.Journal of clinical medicine · 2025Article
- Urinary cystatin-C and urinary NGAL associated with sepsis predicts longer hospital stay in premature newborns.Biomarkers in medicine · 2024Article
- Sepsis, Management & Advances in Metabolomics.Nanotheranostics · 2024Review
- The Significance of Bayesian Pharmacokinetics in Dosing for Critically Ill Patients: A Primer for Clinicians Using Vancomycin as an Example.Antibiotics (Basel, Switzerland) · 2023Review
- Precision management of acute kidney injury in the intensive care unit: current state of the art.Intensive care medicine · 2023Review
- SDS Electrophoresis on Gradient Polyacrylamide Gels as a Semiquantitative Tool for the Evaluation of Proteinuria.Diagnostics (Basel, Switzerland) · 2023Article
- The outcome of acute kidney injury substages based on urinary cystatin C in critically ill children.Annals of intensive care · 2023Article
- Definitions, phenotypes, and subphenotypes in acute kidney injury-Moving towards precision medicine.Nephrology (Carlton, Vic.) · 2023Review
- Improving acute kidney injury diagnostic precision using biomarkers.Practical laboratory medicine · 2022Review
- Downregulation of miR-574-5p inhibits HK-2 cell viability and predicts the onset of acute kidney injury in sepsis patients.Renal failure · 2021Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate the utility of urinary cystatin C (uCysC) as a diagnostic marker of acute kidney injury (AKI) and sepsis, and predictor of mortality in critically ill patients.
methodsThis was a two-center, prospective AKI observational study and post hoc sepsis subgroup analysis of 444 general intensive care unit (ICU) patients. uCysC and plasma creatinine were measured at entry to the ICU. AKI was defined as a 50% or 0.3-mg/dL increase in plasma creatinine above baseline. Sepsis was defined clinically. Mortality data were collected up to 30 days. The diagnostic and predictive performances of uCysC were assessed from the area under the receiver operator characteristic curve (AUC) and the odds ratio (OR). Multivariate logistic regression was used to adjust for covariates.
resultsEighty-one (18%) patients had sepsis, 198 (45%) had AKI, and 64 (14%) died within 30 days. AUCs for diagnosis by using uCysC were as follows: sepsis, 0.80, (95% confidence interval (CI), 0.74 to 0.87); AKI, 0.70 (CI, 0.64 to 0.75); and death within 30 days, 0.64 (CI, 0.56 to 0.72). After adjustment for covariates, uCysC remained independently associated with sepsis, AKI, and mortality with odds ratios (CI) of 3.43 (2.46 to 4.78), 1.49 (1.14 to 1.95), and 1.60 (1.16 to 2.21), respectively. Concentrations of uCysC were significantly higher in the presence of sepsis (P < 0.0001) or AKI (P < 0.0001). No interaction was found between sepsis and AKI on the uCysC concentrations (P = 0.53).
conclusionsUrinary cystatin C was independently associated with AKI, sepsis, and death within 30 days.
trial registrationAustralian New Zealand Clinical Trials Registry ACTRN012606000032550.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.